This DR increased in MTC patients with serum Ctn ≥ 1000 ng/L (75%), CEA ≥ 5 ng/ml (69%), Ctn doubling time < 12 months (76%), and CEA doubling time < 24 months (91%) [28]. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.